In summary, our results suggest that OBP-801 upregulates LMP2, resulting in enhanced MHC class I expression on the surface of ccRCC cells, and combined treatment with OBP-801 and anti-PD-1 antibody creates a synergistic effect with possibly enhanced immunity (Figure 6). This evidence concerns the gene PSMB9 and nonpapillary renal cell carcinoma.